141 related articles for article (PubMed ID: 31288599)
1.
Yang M; Hua Z; Xue L; Hu M
J Biopharm Stat; 2020 Mar; 30(2):244-266. PubMed ID: 31288599
[TBL] [Abstract][Full Text] [Related]
2. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
3. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
4. Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.
Prior TJ
Stat Methods Med Res; 2020 Dec; 29(12):3525-3532. PubMed ID: 32522077
[TBL] [Abstract][Full Text] [Related]
5. Design considerations in clinical trials with cure rate survival data: A case study in oncology.
Sun S; Liu G; Lyu T; Xue F; Yeh TM; Rao S
Pharm Stat; 2018 Mar; 17(2):94-104. PubMed ID: 29159922
[TBL] [Abstract][Full Text] [Related]
6. Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies.
Hasegawa T
Pharm Stat; 2016 Sep; 15(5):412-9. PubMed ID: 27353855
[TBL] [Abstract][Full Text] [Related]
7. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
Kaneko Y; Morita S
J Biopharm Stat; 2023 Aug; ():1-20. PubMed ID: 37585719
[TBL] [Abstract][Full Text] [Related]
8. Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves.
Magirr D; Jiménez JL
Biom J; 2023 Apr; 65(4):e2200126. PubMed ID: 36732918
[TBL] [Abstract][Full Text] [Related]
9. Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies.
Hasegawa T
Pharm Stat; 2014; 13(2):128-35. PubMed ID: 24497461
[TBL] [Abstract][Full Text] [Related]
10. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
11. On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design.
Kundu MG; Sarkar J
Stat Med; 2021 May; 40(10):2321-2338. PubMed ID: 33624861
[TBL] [Abstract][Full Text] [Related]
12. Rational design and identification of immuno-oncology drug combinations.
Iafolla MAJ; Selby H; Warner K; Ohashi PS; Haibe-Kains B; Siu LL
Eur J Cancer; 2018 May; 95():38-51. PubMed ID: 29631102
[TBL] [Abstract][Full Text] [Related]
13. A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects.
He P; Su Z
Contemp Clin Trials Commun; 2015 Oct; 1():28-31. PubMed ID: 29736436
[TBL] [Abstract][Full Text] [Related]
14. N-of-1 trials in oncology.
Collette L; Tombal B
Lancet Oncol; 2015 Aug; 16(8):885-6. PubMed ID: 26248830
[No Abstract] [Full Text] [Related]
15. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
[TBL] [Abstract][Full Text] [Related]
16. Statistical and practical considerations in designing of immuno-oncology trials.
Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
[TBL] [Abstract][Full Text] [Related]
17. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
[TBL] [Abstract][Full Text] [Related]
18. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
19. Immuno-Oncology in China.
Lu S; Chabner BA
Oncologist; 2019 Feb; 24(Suppl 1):S1-S2. PubMed ID: 30819825
[TBL] [Abstract][Full Text] [Related]
20. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).
Liu X; Belani CP
Curr Mol Pharmacol; 2016; 9(3):182. PubMed ID: 26177639
[No Abstract] [Full Text] [Related]
[Next] [New Search]
